AT 03
Alternative Names: AT-03Latest Information Update: 05 Oct 2022
At a glance
- Originator Unknown
- Developer Attralus
- Class Immunoglobulin Fc fragments; Immunoglobulin fusion proteins; Recombinant fusion proteins
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Amyloidosis
Most Recent Events
- 06 Sep 2022 Attralus completes a phase I trial in Amyloidosis (In adults, In the elderly) in USA (IV) (NCT05201911)
- 13 Dec 2021 Pharmacodynamics data from a preclinical trial in amyloidosis released by Attralus
- 11 Dec 2021 Preclinical pharmacodynamic data in systemic amyloidosis presented at the 63rd American Society of Hematology Annual Meeting and Exposition (ASH-2021)